| Followers | 66 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Tuesday, October 05, 2021 10:52:55 AM
Their argument makes sense for traders but not retail. I’ve always had problems with that as well and in retrospect the market was pricing NWBO as a company with a very long road ahead of it when most longs by position (including me) thought the road was much shorter abs bought and held accordingly over time.
This time with data lock and even the not BWBO specific but closely related Lancet articles, we are not waiting until TLD for another year or even six months though I do not think that a ton of stuff is going on behind the scenes like BLA so despite all the wishful thinking a buy out or approval is likely a long way off so folks will have to hang tight fir longer still but those who bought dirt cheap compared to me could exit with fortunes based off of TLD alone and anyone buying now has an excellent short term chance of a 2x to 4x gain (or more if they call the high just right and sell before NWBO gives up that euphoric high and settles back for the wait for approval or a buyout).
This time with data lock and even the not BWBO specific but closely related Lancet articles, we are not waiting until TLD for another year or even six months though I do not think that a ton of stuff is going on behind the scenes like BLA so despite all the wishful thinking a buy out or approval is likely a long way off so folks will have to hang tight fir longer still but those who bought dirt cheap compared to me could exit with fortunes based off of TLD alone and anyone buying now has an excellent short term chance of a 2x to 4x gain (or more if they call the high just right and sell before NWBO gives up that euphoric high and settles back for the wait for approval or a buyout).
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
